Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

10.250
+0.1401.38%
Volume:15.32M
Turnover:155.62M
Market Cap:118.10B
PE:24.54
High:10.250
Open:10.190
Low:9.970
Close:10.110
52wk High:11.454
52wk Low:4.424
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.37
T/O Rate:0.13%
Dividend:0.24
Dividend Rate:2.34%
EPS(LYR):0.418
ROE:10.83%
ROA:5.65%
PB:3.14
PE(LYR):24.54
PS:3.98

Loading ...

Assessing CSPC Pharmaceutical Group (SEHK:1093) Valuation After New Obesity And Pain Drug Trial Clearances

Simply Wall St.
·
Feb 18

CSPC Pharmaceutical (1093) Receives U.S. FDA Nod for Monthly GLP-1/GIP Dual-Biased Injection Trial

Bulletin Express
·
Feb 16

CSPC (1093) Gains Clinical Trial Approval for Ropivacaine Long-acting Injection

Bulletin Express
·
Feb 16

CSPC PHARMA's Long-Acting GLP-1/GIP Dual Agonist Receives FDA Clearance for US Clinical Trials

Stock News
·
Feb 16

BRIEF-CSPC Pharmaceutical Obtains FDA Approval For SYH2082 Clinical Trial

Reuters
·
Feb 16

CSPC PHARMA's Long-Acting Ropivacaine Injection Receives Clearance for Clinical Trials in China

Stock News
·
Feb 16

CSPC Pharmaceutical Group Receives FDA Approval for SYH2082 Clinical Trial in the US

Reuters
·
Feb 16

CSPC Pharmaceutical Group Wins Clinical Trial Approval for Long-Acting Ropivacaine Injection in China

Reuters
·
Feb 16

CSPC Pharmaceutical - Approval From Nmpa

THOMSON REUTERS
·
Feb 16

CSPC Pharmaceutical - Ropivacaine Long-Acting Injection Approved for Clinical Trials in China

THOMSON REUTERS
·
Feb 16

CSPC Pharmaceutical Group Stock Rallies 1.6% in Hong Kong, Outperforms Competitors

Dow Jones
·
Feb 11

AstraZeneca Signs Global Rights Agreement With CSPC for Injectable Weight Management Portfolio

Reuters
·
Feb 10

AstraZeneca Projects Double-Digit EPS Growth Following $18.5 Billion CSPC Pharma Partnership

Deep News
·
Feb 10

CSPC Pharmaceutical Group Stock Rises 5.5% in Hong Kong, Outperforms Competitors

Dow Jones
·
Feb 10

Biopharmaceutical Stocks Show Broad Gains with CSPC PHARMA Leading with Over 7% Rise

Deep News
·
Feb 10

CSPC PHARMA Shares Climb Over 3% as Analysts Foresee Additional Out-Licensing Deals for EGFR ADC and R&D Platform

Stock News
·
Feb 09

Tirzepatide Crowned as New "Blockbuster Drug King" with Rapid Commercial Value Release Expected for Weight Loss Medications

Stock News
·
Feb 05

CSPC Pharmaceutical Group Stock Falls 2.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Feb 04

BUZZ-CSPC Pharmaceutical jumps most in eight months on hypertension drug approval

Reuters
·
Feb 03

HK Stock Movement | CSPC PHARMA (01093) Rises Nearly 6% as Institutions Expect BD Deals to Support Earnings and Dividends

Stock News
·
Feb 03